Tocilizumab in the treatment of adult rheumatoid arthritis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 388(10055), 2023–2038 (2016).Crossref, Medline, CAS, Google Scholar
• 2 Sanmartí R, Ruiz-Esquide V, Hernández MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr. Top. Med. Chem. 13(6), 698–704 (2013).Crossref, Medline, CAS, Google Scholar
• 3 Smolen JS, Landewé R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76(6), 960–977 (2017).Crossref, Medline, Google Scholar
• 4 Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol. 13(4), 234–243 (2017).Crossref, Medline, CAS, Google Scholar
• 5 Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int. Immunol. 27(1), 21–29 (2015).Crossref, Medline, CAS, Google Scholar
• 6 Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68(1), 1–26 (2016).Crossref, Medline, Google Scholar
• 7 Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM et al. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol. Clín. 11(5), 279–294 (2015).Crossref, Medline, Google Scholar
• 8 Lee EB. A review of sarilumab for the treatment of rheumatoid arthritis. Immunotherapy 10(1), 57–65 (2017).Link, Google Scholar
• 9 Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin. Biol. Ther. 17(6), 755–763 (2017).Crossref, Medline, CAS, Google Scholar
• 10 Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. (181), 151–160 (2008).Crossref, Medline, Google Scholar
• 11 Kishimoto T. Interleukin-6: from basic science to medicine--40 years in immunology. Annu. Rev. Immunol. 23(1), 1–21 (2005).Crossref, Medline, CAS, Google Scholar
• 12 Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2(5), 247–56 (2010).Crossref, Medline, CAS, Google Scholar
• 13 Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr. Osteoporos. Rep. 10(2), 101–108 (2012).Crossref, Medline, Google Scholar
• 14 Sweiss N, Shetty A, Hanson R et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des. Devel. Ther. 8, 349 (2014).Crossref, Medline, Google Scholar
• 15 Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol. 50(7), 754–766 (2010).Crossref, Medline, CAS, Google Scholar
• 16 Levi M, Grange S, Frey N. Exposure-exposure relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J. Clin. Pharmacol. 53(2), 151–159 (2013). • Interesting study analyzing the phramacokinetics of tocilizumab (TCZ) intravenously in rheumatoid arthritis (RA) and its association with clinical efficacy.Crossref, Medline, CAS, Google Scholar
• 17 Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10), 3959–64 (2008).Crossref, Medline, CAS, Google Scholar
• 18 Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford) 54(12), 2239–2243 (2015).Medline, Google Scholar
• 19 Abdallah H, Hsu JC, Lu P et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J. Clin. Pharmacol. 57(4), 459–468 (2017).Crossref, Medline, CAS, Google Scholar
• 20 Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50(6), 1761–1769 (2004).Crossref, Medline, CAS, Google Scholar
• 21 Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617), 987–997 (2008).Crossref, Medline, CAS, Google Scholar
• 22 Kremer JM, Blanco R, Brzosko M et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu. Arthritis Rheum. 63(3), 609–621 (2011).Crossref, Medline, CAS, Google Scholar
• 23 Burmester GR, Rigby WF, van Vollenhoven RF et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann. Rheum. Dis. 75(6), 1081–1091 (2016).Crossref, Medline, CAS, Google Scholar
• 24 Bijlsma JWJ, Welsing PMJ, Woodworth TG et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388(10042), 343–355 (2016). •• Strategic study in very early RA analyzing the efficacy of TCZ (in combo or mono) in comparison with methotrexate (MTX). The results favored the use of TCZ as the first strategy in RA.Crossref, Medline, CAS, Google Scholar
• 25 Yazici Y, Curtis JR, Ince A et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann. Rheum. Dis. 71(2), 198–205 (2012).Crossref, Medline, CAS, Google Scholar
• 26 Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58(10), 2968–2980 (2008).Crossref, Medline, CAS, Google Scholar
• 27 Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516–1523 (2008).Crossref, Medline, CAS, Google Scholar
• 28 Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 51(10), 1860–1869 (2012).Crossref, Medline, CAS, Google Scholar
• 29 Kivitz A, Olech E, Borofsky M et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66(11), 1653–1661 (2014).Crossref, Medline, CAS, Google Scholar
• 30 Burmester GR, Rubbert-Roth A, Cantagrel A et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis. 73(1), 69–74 (2014).Medline, CAS, Google Scholar
• 31 Sanmarti R, Mola EM, Fonseca J et al. SAT0183 clinical remission in subjects with rheumatoid arthritis treated with subcutaneous tocilizumab as monotherapy or in combination with methotrexate or other synthetic dmards: a real-world clinical trial (tospace). In: Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism, 840.1–840 (2017).Crossref, Google Scholar
• 32 Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 38(1), 10–20 (2011).Crossref, Medline, Google Scholar
• 33 Bergman GJD, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin. Arthritis Rheum. 39(6), 425–441 (2010).Crossref, Medline, CAS, Google Scholar
• 34 Soliman MM, Ashcroft DM, Watson KD et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 70(4), 583–9 (2011).Crossref, Medline, Google Scholar
• 35 Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J. Rheumatol. 36(8), 1611–1617 (2009).Crossref, Medline, CAS, Google Scholar
• 36 Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675–681 (2004).Crossref, Medline, CAS, Google Scholar
• 37 Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636), 375–382 (2008).Crossref, Medline, CAS, Google Scholar
• 38 Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 60(8), 2272–2283 (2009).Crossref, Medline, CAS, Google Scholar
• 39 Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26–37 (2006).Crossref, Medline, CAS, Google Scholar
• 40 Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69(1), 88–96 (2010). •• Randomized clinical trial comparing the efficacy of TCZ and MTX, both in monotherapy, in RA. TCZ was superior to MTX, which was not observed with TNF inhibitors.Crossref, Medline, CAS, Google Scholar
• 41 Nishimoto N, Miyasaka N, Yamamoto K et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19(1), 12–19 (2009).Medline, CAS, Google Scholar
• 42 Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162–1167 (2007).Crossref, Medline, CAS, Google Scholar
• 43 Dougados M, Kissel K, Conaghan PG et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann. Rheum. Dis. 73, 803–809 (2014).Crossref, Medline, CAS, Google Scholar
• 44 Huizinga TWJ, Conaghan PG, Martin-Mola E et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann. Rheum. Dis. 74(1), 35–43 (2015).Crossref, Medline, CAS, Google Scholar
• 45 Kaneko Y, Atsumi T, Tanaka Y et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann. Rheum. Dis. 75(11), 1917–1923 (2016).Crossref, Medline, CAS, Google Scholar
• 46 Weinblatt ME, Kremer J, Cush J et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res. (Hoboken). 65(3), 362–371 (2013). •• Head-to-head clinical trial in RA comparing TCZ and adalimumab, both in monotherapy. Clinical outcomes were better with TCZ.Crossref, Medline, CAS, Google Scholar
• 47 Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled Phase IV trial. Lancet 381(9877), 1541–1550 (2013).Crossref, Medline, CAS, Google Scholar
• 48 Teitsma XM, Jacobs JWG, Welsing PMJ et al. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatology 57(2), 309–317 (2017).Crossref, Google Scholar
• 49 Edwards CJ, J K Östör A, Naisbett-Groet B, Kiely P. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. Rheumatology (Oxford) 57(1), 84–91 (2018).Crossref, Medline, CAS, Google Scholar
• 50 Strand V, Michalska M, Birchwood C et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. RMD Open 3(2), e000496 (2017).Crossref, Medline, Google Scholar
• 51 Ogata A, Tanimura K, Sugimoto T et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66(3), 344–354 (2014).Crossref, Medline, CAS, Google Scholar
• 52 Ogata A, Tanaka Y, Ishii T et al. A randomized, double-blind, parallel-group, Phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: results of the 12-week double-blind period. Mod. Rheumatol. 28(1), 76–84 (2017).Medline, Google Scholar
• 53 Gabay C, Riek M, Scherer A, Finckh A, SCQM collaborating physicians. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 54(9), 1664–1672 (2015).Crossref, Medline, CAS, Google Scholar
• 54 Gabay C, Riek M, Hetland ML et al. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann. Rheum. Dis. 75(7), 1336–1342 (2016).Crossref, Medline, CAS, Google Scholar
• 55 Kojima T, Yabe Y, Kaneko A et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford) 54(1), 113–120 (2015).Crossref, Medline, CAS, Google Scholar
• 56 Bykerk VP, Östör AJK, Alvaro-Gracia J et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann. Rheum. Dis. 71(12), 1950–1954 (2012).Crossref, Medline, CAS, Google Scholar
• 57 Balsa A, Tovar Beltrán JV, Cáliz Cáliz R et al. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol. Int. 35(9), 1525–1534 (2015).Crossref, Medline, CAS, Google Scholar
• 58 Flipo R-M, Maillefert J-F, Chazerain P, Idier I, Coudert M, Tebib J. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study. RMD Open 3(1), e000340 (2017).Crossref, Medline, Google Scholar
• 59 Kihara M, Davies R, Kearsley-Fleet L et al. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin. Rheumatol. 36(2), 241–250 (2017).Crossref, Medline, Google Scholar
• 60 Backhaus M, Kaufmann J, Richter C et al. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin. Rheumatol. 34(4), 673–681 (2015).Crossref, Medline, Google Scholar
• 61 Choy E, Caporali R, Xavier R et al. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework Phase IV study programme TOZURA conducted in 22 countries. Rheumatology doi:10.1093/rheumatology/kex443 (2017) (Epub ahead of print).Google Scholar
• 62 Iannone F, Ferraccioli G, Sinigaglia L et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. Clin. Rheumatol. 37(2), 315–321 (2017).Crossref, Medline, Google Scholar
• 63 Enevold C, Baslund B, Linde L et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet. Genomics 24(8), 1 (2014).Crossref, Medline, Google Scholar
• 64 Sanayama Y, Ikeda K, Saito Y et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol. 66(6), 1421–1431 (2014).Crossref, Medline, CAS, Google Scholar
• 65 Gardette A, Ottaviani S, Sellam J et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin. Rheumatol. 35(4), 857–861 (2016).Crossref, Medline, CAS, Google Scholar
• 66 Pers Y-M, Godfrin-Valnet M, Lambert J et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J. Rheumatol. 42(4), 580–584 (2015).Crossref, Medline, CAS, Google Scholar
• 67 Theander E, Proven A, Fallang A, Svelander L, Trollmo T. FRI0163 smoking status does not seem to affect tocilizumab efficacy in RA patients. Ann. Rheum. Dis. 74(Suppl. 2), 482.1 (2015).Crossref, Google Scholar
• 68 Martin-Mola E, Balsa A, García-Vicuna R et al. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol. Int. 36(8), 1043–1063 (2016).Crossref, Medline, CAS, Google Scholar
• 69 Narváez J, Magallares B, Díaz Torné C et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin. Arthritis Rheum. 45(4), 386–390 (2016).Crossref, Medline, CAS, Google Scholar
• 70 Wang J, Devenport J, Low JM, Yu D, Hitraya E. Relationship between baseline and early changes in C-Reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 68(6), 882–885 (2016). • Accurate analysis of the safety profile of TCZ in an integrated analysis of clinical trials.Crossref, Medline, CAS, Google Scholar
• 71 Diaz-Torne C, Ortiz M dels A, Moya P et al. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Semin. Arthritis Rheum. doi:10.1016/j.semarthrit.2017.10.022 (2017) (Epub ahead of print).Crossref, Medline, Google Scholar
• 72 Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 13(5), R141 (2011).Crossref, Medline, Google Scholar
• 73 Genovese MC, Rubbert-Roth A, Smolen JS et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J. Rheumatol. 40(6), 768–780 (2013).Crossref, Medline, CAS, Google Scholar
• 74 Strand V, Ahadieh S, French J et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res. Ther. 17(1), 362 (2015).Crossref, Medline, Google Scholar
• 75 Morel J, Constantin A, Baron G et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford) 56(10), 1746–1754 (2017).Crossref, Medline, CAS, Google Scholar
• 76 Iking-Konert C, von Hinüber U, Richter C et al. ROUTINE–a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology 55(4), 624–635 (2016). • Updated analysis of the safety profile of biologics in RA, including TCZ.Crossref, Medline, CAS, Google Scholar
• 77 Fujiwara H, Nishimoto N, Hamano Y et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod. Rheumatol. 19(1), 64–68 (2009).Crossref, Medline, Google Scholar
• 78 Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin. Biol. Ther. 17(9), 1089–1103 (2017).Crossref, Medline, CAS, Google Scholar
• 79 Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann. Rheum. Dis. 75(10), 1843–1847 (2016).Crossref, Medline, CAS, Google Scholar
• 80 Chen L-F, Mo Y-Q, Jing J, Ma J-D, Zheng D-H, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int. J. Rheum. Dis. 20(7), 859–869 (2017).Crossref, Medline, CAS, Google Scholar
• 81 Bingham CO, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann. Rheum. Dis. 74(5), 818–822 (2015).Crossref, Medline, CAS, Google Scholar
• 82 Rubbert-Roth A, Sebba A, Brockwell L et al. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open 2(1), e000213 (2016).Crossref, Medline, Google Scholar
• 83 Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. JAMA Intern. Med. 177(11), 1605 (2017).Crossref, Medline, Google Scholar
• 84 Li Y, Zhong X, Cheng G et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis 259, 75–82 (2017).Crossref, Medline, CAS, Google Scholar
• 85 Rao VU, Pavlov A, Klearman M et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 67(2), 372–380 (2015).Crossref, Medline, CAS, Google Scholar
• 86 Giles JT. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, Phase IV clinical trial - ACR meeting abstracts. Arthritis Rheumatol. 68(Suppl. 10), 2–4 (2016).Google Scholar
• 87 Kim SC, Solomon DH, Rogers JR et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol. 69(6), 1154–1164 (2017).Crossref, Medline, CAS, Google Scholar
• 88 Gualtierotti R, Ingegnoli F, Griffini S, Grovetti E, Meroni PL, Cugno M. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. Clin. Exp. Rheumatol. 34(3), 451–8 (2016).Medline, Google Scholar
• 89 McInnes IB, Thompson L, Giles JT et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis. 74(4), 694–702 (2015).Crossref, Medline, CAS, Google Scholar
• 90 Gabay C, McInnes IB, Kavanaugh A et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 75(10), 1806–1812 (2016).Crossref, Medline, Google Scholar
• 91 García-Gómez C, Martín-Martínez MA, Castañeda S et al. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project. J. Clin. Lipidol. 11(3), 749.e3–756.e3 (2017).Crossref, Google Scholar
• 92 Soubrier M, Pei J, Durand F, Gullestad L, John A. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: a post hoc analysis. Rheumatol. Ther. 4(1), 133–149 (2017). • Excellent review of the effects of IL-6 in the host defense against infections and its clinical consequences.Crossref, Medline, Google Scholar
• 93 Burmester GR, Lin Y, Patel R et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group Phase III trial. Ann. Rheum. Dis. 76(5), 840–847 (2017).Crossref, Medline, CAS, Google Scholar
• 94 Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13(7), 399–409 (2017).Crossref, Medline, CAS, Google Scholar
• 95 Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology 53(7), 1321–1331 (2014).Crossref, Medline, CAS, Google Scholar
• 96 Lok LSC, Farahi N, Juss JK et al. Effects of tocilizumab on neutrophil function and kinetics. Eur. J. Clin. Invest. 47(10), 736–745 (2017).Crossref, Medline, CAS, Google Scholar
• 97 Moots RJ, Sebba A, Rigby W et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from Phase III and IV clinical trials. Rheumatology 56(4), kew370 (2016).Crossref, Google Scholar
• 98 Genovese MC, Kremer JM, van Vollenhoven RF et al. Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol. 69(9), 1751–1761 (2017).Crossref, Medline, CAS, Google Scholar
• 99 Burmester GR, Choy E, Kivitz A et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 76(6), 1078–1085 (2017).Crossref, Medline, CAS, Google Scholar
• 100 Hoeltzenbein M, Beck E, Rajwanshi R et al. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Semin. Arthritis Rheum. 46(2), 238–245 (2016).Crossref, Medline, CAS, Google Scholar
• 101 Götestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75(5), 795–810 (2016).Crossref, Medline, Google Scholar
• 102 Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 68(11), 2612–2617 (2016).Crossref, Medline, CAS, Google Scholar
• 103 Strangfeld A, Richter A, Siegmund B et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann. Rheum. Dis. 76(3), 504–510 (2017).Crossref, Medline, CAS, Google Scholar